报价延迟最少15分钟:2025/07/21 06:41 EDT
盘前时段
|
||||
|
0.3336 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.344
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-1.67/-0.53
|
|
企业价值
14.13M
|
| 资产负债 |
|
每股账面净值
0.50
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
0.04
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 06:41 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Leap Therapeutics Inc is a biopharmaceutical company developing novel biomarker-targeted antibody therapies designed to treat patients with cancer by inhibiting fundamental tumor-promoting pathways, targeting cancer-specific cell surface molecules, and harnessing the immune system to attack cancer cells. The company's key clinical-stage drug candidate is sirexatamab (DKN-01), which targets Dickkopf-related protein 1 (DKK1) and is being studied in a clinical trial in patientswith colorectal cancer. In addition, it also has a preclinical program to develop a proprietary monoclonal antibody, called FL-501 which works by inhibiting the GDF-15 protein. |
